JP2024504931A5 - - Google Patents

Info

Publication number
JP2024504931A5
JP2024504931A5 JP2023541914A JP2023541914A JP2024504931A5 JP 2024504931 A5 JP2024504931 A5 JP 2024504931A5 JP 2023541914 A JP2023541914 A JP 2023541914A JP 2023541914 A JP2023541914 A JP 2023541914A JP 2024504931 A5 JP2024504931 A5 JP 2024504931A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/050359 external-priority patent/WO2022152656A1/en
Publication of JP2024504931A publication Critical patent/JP2024504931A/ja
Publication of JP2024504931A5 publication Critical patent/JP2024504931A5/ja
Pending legal-status Critical Current

Links

JP2023541914A 2021-01-12 2022-01-10 がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体 Pending JP2024504931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21151245.4 2021-01-12
EP21151245 2021-01-12
PCT/EP2022/050359 WO2022152656A1 (en) 2021-01-12 2022-01-10 Split antibodies which bind to cancer cells and target radionuclides to said cells

Publications (2)

Publication Number Publication Date
JP2024504931A JP2024504931A (ja) 2024-02-02
JP2024504931A5 true JP2024504931A5 (cg-RX-API-DMAC7.html) 2025-01-15

Family

ID=74175694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541914A Pending JP2024504931A (ja) 2021-01-12 2022-01-10 がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体

Country Status (16)

Country Link
US (1) US20240082437A1 (cg-RX-API-DMAC7.html)
EP (1) EP4277705A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024504931A (cg-RX-API-DMAC7.html)
KR (1) KR20230131204A (cg-RX-API-DMAC7.html)
CN (1) CN116829593A (cg-RX-API-DMAC7.html)
AR (1) AR124609A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022207615A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206466A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001989A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009153A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230385A (cg-RX-API-DMAC7.html)
IL (1) IL304224A (cg-RX-API-DMAC7.html)
MX (1) MX2023008084A (cg-RX-API-DMAC7.html)
PE (1) PE20240690A1 (cg-RX-API-DMAC7.html)
TW (1) TW202241962A (cg-RX-API-DMAC7.html)
WO (1) WO2022152656A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL330142A (en) 2024-02-20 2026-08-01 F Hoffmann La Roche Ag New Antibodies for Pre-Targeting and Their Uses

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5846535A (en) 1990-10-12 1998-12-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2378403A1 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
WO2007071422A2 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2403530B1 (en) 2009-02-27 2016-05-11 Massachusetts Institute of Technology Engineered proteins with high affinity for dota chelates
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
MX359411B (es) * 2012-01-13 2018-09-27 Univ Wuerzburg J Maximilians Complementación funcional bipartita inducida por antígenos, dual.
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-수용체 기재 친화성 크로마토그래피
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
HUE054131T2 (hu) * 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
EP3759135A1 (en) * 2017-12-21 2021-01-06 Gernot Stuhler Specific dosage regimen for hemibody therapy
KR102884852B1 (ko) 2018-04-16 2025-11-14 에프. 호프만-라 로슈 아게 킬레이트화된 방사성핵종에 대한 항체
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
WO2022008688A1 (en) * 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells

Similar Documents

Publication Publication Date Title
US8901278B2 (en) Pharmaceutical antibody compositions with resistance to soluble CEA
JP2024056687A5 (cg-RX-API-DMAC7.html)
DK1976880T3 (en) Pharmaceutical compositions with resistance to soluble cea
CN101035809B (zh) 抗tag-72的人源化单克隆抗体
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2022506072A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2022540610A5 (cg-RX-API-DMAC7.html)
JP2010504755A5 (cg-RX-API-DMAC7.html)
FI3781200T3 (fi) Kelatoituneiden radionuklidien vasta-aineita
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2018507188A5 (cg-RX-API-DMAC7.html)
JP7419238B2 (ja) Pd1結合剤
JP2023533533A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP2025510189A5 (cg-RX-API-DMAC7.html)
US20230312742A1 (en) CD38 antibodies for the treatment of human diseases
JP2018526975A (ja) Cys80抱合型免疫グロブリン
JP2023549316A5 (cg-RX-API-DMAC7.html)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2023549555A5 (cg-RX-API-DMAC7.html)
JP2025510642A5 (cg-RX-API-DMAC7.html)
JP2025513745A5 (cg-RX-API-DMAC7.html)
JP2024020436A5 (cg-RX-API-DMAC7.html)